## Does Gestala's $84M Ultrasound Bet Signal a New Direction for BCI?

[Gestala](https://bciintel.com/companies/gestala), the Shanghai- and Chengdu-based [brain-computer interface](https://bciintel.com/glossary/brain-computer-interface) startup that launched on January 1, 2026, has closed two financing rounds totaling RMB 570 million (approximately US$84 million) in its first six months of operation. The angel round of RMB 150 million closed in March; a larger RMB 420 million Angel+ round closed in July. Investors in the latest tranche include HSG, Lens Technology, Sinovation Ventures, and C Capital, with follow-on participation from Dalton Venture, Seas Capital, Tsing Song Capital, and Gobi Partners.

The speed and scale of that capital formation is notable in any geography. What makes it analytically interesting is the underlying technical thesis: Gestala is explicitly positioning ultrasound — functional ultrasound imaging for neural readout and focused ultrasound for neuromodulation — as a complement or longer-term alternative to implantable [electrode arrays](https://bciintel.com/glossary/electrode-array). Its stated ambition is whole-brain read and write capability, targeting higher-order functions including memory, emotion, language, and movement planning that current intracortical electrode approaches cannot easily access at scale.

The company has 29 scientists and engineers and plans to reach approximately 45 by year-end, according to the source material. Its first product remains in development and clinical preparation — no human trial data has been published.

---

## Who Is Behind Gestala

The company was co-founded by Phoenix Peng and Tianqiao Chen, founder of Shanda Group and the Tianqiao and Chrissy Chen Institute. Peng holds a doctorate from Fudan University's Institute of Science and Technology for Brain-Inspired Intelligence and is a Principal Investigator at Tianfu Jincheng Laboratory. Gestala is his sixth startup; he previously co-founded NeuroXess, which pursues an invasive intracortical electrode approach.

The pivot from electrodes to ultrasound is not a rejection of the electrode paradigm — Peng is explicit about that in the source material, acknowledging that intracortical recording offers high temporal resolution and has demonstrated clinical potential in motor and speech decoding. His argument is one of scope: if the clinical target expands beyond cursor control or device actuation toward broader cognitive functions, observing a small number of neurons or isolated cortical regions may be structurally insufficient.

Between April and May 2026, Gestala recruited a former [Neuralink](https://bciintel.com/companies/neuralink) clinical lead and senior R&D and regulatory personnel from Nano Retina, described in the source as a visual BCI company. The regulatory hiring, in particular, signals that the company is building toward a clinical submission pathway, though no regulatory designation or trial identifier has been announced.

---

## The Ultrasound BCI Thesis: Genuine Differentiation or Premature Ambition?

Gestala's technical approach centers on two distinct modalities. Functional ultrasound imaging (fUSI) measures hemodynamic changes associated with neural activity — analogous in principle to fMRI but potentially portable and wearable. Focused ultrasound enables non-contact modulation of specific brain regions, including deep subcortical circuits that are difficult to reach with surface ECoG or even penetrating electrode arrays without highly invasive procedures.

The name Gestala itself is derived from Gestalt psychology — the principle that the whole is greater than the sum of its parts — which the company uses to frame its whole-brain systems philosophy.

**The genuine technical challenges here deserve direct treatment:**

**Hemodynamic coupling lag.** Functional ultrasound measures blood flow changes, not neuronal firing. The neurovascular coupling that links the two introduces temporal resolution constraints that intracortical spike sorting does not face. For applications requiring high-bandwidth decoding — speech synthesis, fine motor control — this is a meaningful limitation that the source material acknowledges but does not resolve.

**Skull acoustics.** Variations in skull thickness and anatomy attenuate, scatter, and distort acoustic waves. This is not a trivial engineering problem, particularly for a device aiming at broad cortical and subcortical coverage rather than a single focal target like therapeutic focused ultrasound for essential tremor.

**The AI dependency.** Gestala plans to develop what it calls a multimodal brain foundation model — integrating neural activity signals, cerebral blood flow data, medical imaging, and behavioral observations. The company's decoding pipeline is therefore downstream of AI model quality in a way that intracortical decoding, which benefits from decades of spike sorting methods, currently is not. This is a platform bet as much as a hardware bet.

None of this means the approach is wrong. Functional ultrasound has produced compelling preclinical results in non-human primates, and the focused ultrasound neuromodulation field has clinical traction in psychiatry applications. But investors and engineers evaluating Gestala should register that the company's stated long-term goal — whole-brain read and write — is considerably further from clinical reality than the near-term milestones its six-month operational pace might suggest.

---

## What This Means for the BCI Industry

The capital flowing into Gestala reflects a broader pattern: investors are not exclusively betting on the intracortical electrode paradigm that currently dominates clinical BCI. [Synchron](https://bciintel.com/companies/synchron)'s endovascular Stentrode, Precision Neuroscience's thin-film cortical surface approach, and now Gestala's ultrasound platform represent distinct points on the invasiveness-coverage tradeoff curve. Each involves a different answer to the same underlying question: how much neural information, from how much of the brain, at what biological cost to the patient?

For China specifically, Gestala's trajectory fits a state-supported push into neurotechnology. The company's decision to base its manufacturing superfactory in Chengdu — which began first-phase operations in June 2026 — and its global headquarters in Shanghai suggests deliberate positioning within China's domestic innovation infrastructure.

The recruitment of a former Neuralink clinical lead is worth tracking. Personnel movement from U.S. to Chinese BCI firms carries regulatory and intellectual property implications that the source does not address. As the FDA and NMPA (China's National Medical Products Administration) develop their respective frameworks for novel neural interface modalities, the regulatory pathway for a non-implanted ultrasound BCI system may actually be more tractable than for penetrating intracortical arrays — a potential structural advantage for Gestala if the technology performs.

**Clinical translation timeline:** No trial IDs have been disclosed. With a 29-person team, manufacturing under construction, and a product in pre-clinical development, a first-in-human feasibility study is likely at minimum 18–24 months away. The RMB 570 million in hand provides sufficient runway for that stage if burn is managed, but the company's self-described simultaneous build-out across research, manufacturing, clinical, and AI functions raises legitimate questions about capital allocation discipline at an early stage.

---

## Key Takeaways

- **$84M in six months:** Gestala closed RMB 150M (March) and RMB 420M (July) rounds totaling approximately US$84 million since its January 1, 2026 launch.
- **Ultrasound, not electrodes:** The company is pursuing functional ultrasound imaging for neural readout and focused ultrasound for neuromodulation — a non-implanted approach targeting whole-brain coverage.
- **Technical caveats are real:** Hemodynamic coupling lag, skull acoustics, and AI model dependency are unresolved challenges that the company acknowledges but has not yet demonstrated solutions for.
- **No clinical data yet:** Gestala's first product is in development and clinical preparation; no trial identifier or regulatory designation has been disclosed.
- **Team and hiring:** 29 staff currently, targeting approximately 45 by end of 2026; recruited a former Neuralink clinical lead and Nano Retina regulatory personnel.
- **China strategic context:** Chengdu superfactory and Shanghai HQ reflect deliberate positioning within China's neurotechnology infrastructure push.

---

## Frequently Asked Questions

**What is Gestala and what does it do?**
Gestala is a Chinese brain-computer interface startup founded January 1, 2026, that is developing ultrasound-based neural interfaces — using functional ultrasound imaging to read brain activity and focused ultrasound to modulate specific neural circuits. It is pursuing a non-implanted alternative to electrode-based BCIs.

**How much has Gestala raised and from whom?**
Gestala has raised approximately US$84 million (RMB 570 million) across two rounds: a RMB 150 million angel round in March 2026 and a RMB 420 million Angel+ round in July 2026. Investors include HSG, Lens Technology, Sinovation Ventures, C Capital, Dalton Venture, Seas Capital, Tsing Song Capital, and Gobi Partners.

**How does ultrasound BCI differ from Neuralink or Synchron?**
Neuralink uses penetrating intracortical electrode arrays implanted in the cortex; Synchron uses an endovascular device placed in a blood vessel near the motor cortex. Gestala's ultrasound approach does not require implantation, instead measuring hemodynamic changes associated with neural activity through the skull — offering lower invasiveness but accepting tradeoffs in temporal resolution and signal fidelity.

**Has Gestala started clinical trials?**
No. As of August 2026, Gestala's product is in development and clinical preparation. No trial registration number or regulatory designation has been publicly disclosed.

**Why are investors backing non-electrode BCI approaches?**
Electrode-based BCIs face challenges including signal degradation over time, limited spatial coverage, and surgical risk. Ultrasound and other non-implanted approaches offer potential advantages in safety profile, brain coverage, and patient accessibility — though they currently trail intracortical systems on temporal resolution and demonstrated clinical evidence.

---

*Disclaimer: This article is based on a single press release source distributed via PR Newswire. No independently verified clinical data, peer-reviewed publications, or regulatory filings have been cited, as none were available in the source material. Gestala's technology claims reflect the company's stated goals and have not been validated in published human studies. Nothing here constitutes medical advice or investment recommendation.*